


PHARMACEUTICAL 2018



RELMADA THERAPEUTICS INC. Rank 298 of 342







PHARMACEUTICAL 2018



RELMADA THERAPEUTICS INC. Rank 298 of 342

The relative strengths and weaknesses of RELMADA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RELMADA THERAPEUTICS INC. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 43% points. The greatest weakness of RELMADA THERAPEUTICS INC. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 217% points.

The company's Economic Capital Ratio, given in the ranking table, is -179%, being 225% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	2,475
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,377
Liabilities, Non-Current	0
Other Assets	360
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	932
Other Revenues	0
Property and Equipment	2.3
Research and Development	1,293
Selling, General and Administrative Expense	5,925

Output Variable	Value in 1000 USD
Assets	2,837
Liabilities	1,377
Expenses	7,219
Revenues	0
Stockholders Equity	1,460
Net Income	-6,287
Comprehensive Net Income	-6,287
Economic Capital Ratio	-179%

